We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

73 hedge funds and large institutions have $285M invested in Tetraphase Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

54% more capital invested

Capital invested by funds: $185M → $285M (+$99.9M)

29% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 17

14% more funds holding

Funds holding: 6473 (+9)

6% less call options, than puts

Call options by funds: $2.16M | Put options by funds: $2.29M

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
73
Holders Change
+9
Holders Change %
+14.06%
% of All Funds
2.12%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
18
Increased
22
Reduced
17
Closed
9
Calls
$2.16M
Puts
$2.29M
Net Calls
-$134K
Net Calls Change
-$447K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$42.3M -$1.84M -6,866 -6%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$30.2M -$386K -1,440 -2%
BC
3
Broadfin Capital
New York
$19.1M -$15.5M -57,825 -55%
NHAS
4
Novo Holdings A/S
Denmark
$18M
Jennison Associates
5
Jennison Associates
New York
$12.9M +$13.1K +49 +0.2%
Vanguard Group
6
Vanguard Group
Pennsylvania
$10.4M +$475K +1,774 +7%
BFA
7
BlackRock Fund Advisors
California
$10.4M -$177K -660 -2%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$10.1M +$6.76M +25,227 New
Millennium Management
9
Millennium Management
New York
$9.98M -$1.57M -5,856 -19%
CPIM
10
Columbia Partners Investment Management
Virginia
$9.93M +$5.11M +19,065 +327%
DM
11
Deerfield Management
New York
$8.98M +$1.88M +7,009 +45%
Fidelity International
12
Fidelity International
Bermuda
$8.88M +$5.96M +22,249 New
HCM
13
Harvey Capital Management
Florida
$7.07M +$30.8K +115 +0.7%
GIM
14
Granahan Investment Management
Massachusetts
$6.15M +$4.13M +15,418 New
EAM
15
Eventide Asset Management
Massachusetts
$6M
PC
16
PointState Capital
New York
$5.99M -$5.36M -20,000 -57%
State Street
17
State Street
Massachusetts
$5.38M +$363K +1,354 +11%
Nomura Holdings
18
Nomura Holdings
Japan
$4.86M +$3.39M +12,658 New
CA
19
Commerzbank Aktiengesellschaft
Germany
$4.6M +$3.09M +11,538 New
Northern Trust
20
Northern Trust
Illinois
$4.5M +$881K +3,291 +41%
Wells Fargo
21
Wells Fargo
California
$4.4M -$1.8M -6,729 -38%
BIT
22
BlackRock Institutional Trust
California
$4.21M -$958K -3,577 -25%
OM
23
Opaleye Management
Massachusetts
$3.39M
EI
24
EAM Investors
California
$3.04M +$2.04M +7,630 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$2.92M +$779K +2,909 +66%

TTPH Hedge Fund Activity: Q3 2014 in Review

73 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q3 2014, worth a combined $285M — up 54% from $185M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new TTPH positions and 9 closed out — a net gain of 9 holders — while 22 added to existing stakes and 17 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $6.76M. The largest seller was Broadfin Capital, cutting an estimated $15.5M.

  • 73 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q3 2014, up from 64 in Q2 2014.
  • Funds reported $285M of Tetraphase Pharmaceuticals, Inc. stock for Q3 2014, up 54% quarter-over-quarter.
  • 18 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q3 2014 and 9 closed out, a net change of +9 holders.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q3 2014 was Adage Capital Partners, an estimated $6.76M added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q3 2014 was Broadfin Capital, an estimated $15.5M sold.

Based on aggregated 13F filings for Q3 2014.